2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Potassium Channel

Potassium Channel

KcsA

Potassium Channel

Related Products

PDF 4.25 MB

Potassium channels are the most widely distributed type of ion channel and are found in virtually all living organisms. They form potassium-selective pores that span cell membranes. Potassium channels are found in most cell types and control a wide variety of cell functions. Potassium channels function to conduct potassium ions down their electrochemical gradient, doing so both rapidly and selectively. Biologically, these channels act to set or reset the resting potential in many cells. In excitable cells, such asneurons, the delayed counterflow of potassium ions shapes the action potential. By contributing to the regulation of the action potential duration in cardiac muscle, malfunction of potassium channels may cause life-threatening arrhythmias. Potassium channels may also be involved in maintaining vascular tone.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-156335
    VU0531245
    		Inhibitor
    VU0531245 is a SLACK channel inhibitor (IC50: 2.1 μM).
    VU0531245
  • HY-W396714
    Succinic acid sodium
    		Inhibitor
    Succinic acid sodium is a potent and orally active anxiolytic agent. Succinic acid sodium shows inhibitory effects on colonic epithelial cell proliferation in vivo. Succinic acid sodium can down-regulate the expression of KCNMB1 (potassium channel subunit β1) and TET1 (ten?eleven translocation 1). Succinic acid sodium can be used for gestational hypertension research.
    Succinic acid sodium
  • HY-117223
    GEA 857
    		Inhibitor
    GEA 857 is a structural analog of the Serotonin (HY-B1473A) uptake blocker Alaproclate (HY-164011). GEA 857 enhances responses induced by muscarinic receptor agonists by inhibiting certain calcium-dependent potassium channels on membranes, a blockade that can enhance or prolong the muscarinic cholinergic effects. GEA 857 can be used in research on neurodegenerative diseases.
    GEA 857
  • HY-B1239A
    Drofenine
    		Inhibitor
    Drofenine (Cycloadiphene; Hexahydroadiphenine) is an brain-penetrant antispasmodic agent. Drofenine is a Kv2.1 channel inhibitor with human IC50 of 9.53 μM. Drofenine is a butyrylcholinesterase (BChE) inhibitor with Ki of 0.003 mM, and is a TRPV3 activator. Drofenine blocks Kv2.1-dependent potassium efflux, inhibits Kv2.1/JNK/NF-κB and IkBa/NF-kB signaling, suppresses Kv2.1 mRNA/protein expression. Drofenine suppresses oligomeric Aβ-induced microglial NLRP3 inflammasome activation and neuronal Tau hyperphosphorylation, improves cognitive impairment, promotes neurite outgrowth. Drofenine induces calcium influx in keratinocytes and exert cytotoxicity against keratinocytes. Drofenine ameliorates diabetic peripheral neuropathy -like pathology. Drofenine can be used for the researches of Alzheimer's disease, diabetic peripheral neuropathy and smooth muscle spasm.
    Drofenine
  • HY-19049
    CK-1649 chloride
    		Inhibitor
    CK-1649 chloride is a class III antiarrhythmic agent. CK-1649 chloride can inhibit potassium channel activity.
    CK-1649 chloride
  • HY-P5182
    HsTX1
    		Inhibitor
    HsTX1, from the scorpion Heterometrus spinnifer, is a 34-residue, C-terminally amidated peptide cross-linked by four disulfide bridges. HsTX1, an the inhibitor of potassium channel, with IC50 for Kv1.3 of 12 pM inhibits TEM cell activation and attenuates inflammation in autoimmunity.
    HsTX1
  • HY-178928
    KV1.3-IN-3
    		Inhibitor
    KV1.3-IN-3 (Compound 13a) is a KV1.3 channel inhibitor. KV1.3-IN-3 decreases the Kv1.3 peak current amplitude by more than 80%. KV1.3-IN-3 exhibits excellent pharmacological properties and safety. KV1.3-IN-3 can be used for the study of autoimmunity disease.
    KV1.3-IN-3
  • HY-153952
    Immuno modulator-1
    		Inhibitor
    Immuno modulator-1 (compound 22) inhibits TNFα and IL-2 secretion in human peripheral blood mononuclear cells (hPBMC), with IC50 values of 4.7 and 26 nM, respectively. Immuno modulator-1 shows hERG potassium channel blocking effect, with Inhibitory percentage of 20% at 3 μM.
    Immuno modulator-1
  • HY-117528
    WAY-123398
    		Inhibitor
    WAY-123398 is a class III antiarrhythmic agent. WAY-123398 is a selective blocker of the delayed rectifier K+ current.
    WAY-123398
  • HY-B1751S1
    Quinidine-13C, d2 hydrochloride
    		Inhibitor
    Quinidine-13C, d2 hydrochloride is the deuterium and 13C-labeled Quinidine (HY-B1302). Quinidine hydrochloride monohydrate is an anti-arrythmic agent which is also a potent blocker of K+ channel with an IC50 of 19.9 μM.
    Quinidine-<sup>13</sup>C, d<sub>2</sub> hydrochloride
  • HY-119211
    LY 97241
    		Inhibitor
    LY 97241 accelerates the apparent rate of inactivation of transient outward K current. LY 97241 is an antiarrhythmic drug.
    LY 97241
  • HY-N1934R
    Dihydroberberine (Standard)
    		Inhibitor
    Dihydroberberine (Standard) is the analytical standard of Dihydroberberine. This product is intended for research and analytical applications. Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy.
    Dihydroberberine (Standard)
  • HY-P5156
    BDS-I
    		Inhibitor
    BDS-I known as blood depressing substance, is a marine toxin which can be extracted from Anemonia sulcata. BDS-I is a specific inhibitor of Potassium Channel, targeting to Kv3.4. BDS-I inhibits Aβ1-42-induced enhancement of KV3.4 activity, caspase-3 activation, and abnormal nuclear morphology of NGF-differentiated PC-12 cells. BDS-I reverts the Aβ peptide-induced cell death.
    BDS-I
  • HY-178058
    VU6080824
    		Inhibitor
    VU6080824 (Compound 5s), a derivative of ML-133 (HY-100230), is an inward-rectifier potassium channel (Kir2.1) inhibitor with an IC50 of 0.35  μM. VU6080824 has superior thallium flux and manual patch clamp (MPC) functional potency.
    VU6080824
  • HY-14924
    Inakalant
    		Inhibitor
    Inakalant is an atrial specific potassium channel blocker with antiarrhythmic activity. Inakalant works by selectively blocking potassium channels in heart cells, thereby prolongs the action potential duration (APD) of cardiomyocytes and increases the effective refractory period of the atria and ventricles, which helps to terminate and prevent the occurrence of arrhythmias such as atrial fibrillation (AF). Inakalant can be used in the study of arrhythmia and cardiac electrophysiology.
    Inakalant
  • HY-117275A
    Meclofenamic acid sodium hydrate
    		Inhibitor
    Meclofenamic acid (Meclofenamate) sodium hydrate is a non-steroidal anti-inflammatory agent. Meclofenamic acid sodium hydrate is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid sodium hydrate competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid sodium hydrate is a non-selective gap-junction blocker. Meclofenamic acid sodium hydrate inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
    Meclofenamic acid sodium hydrate
  • HY-W013727
    UK-78282 hydrochloride
    		Inhibitor 99.82%
    UK-78282, a novel piperidine, potent and selective Kv1.3 blocker with an IC50 of 200 nM. UK-78,282 effectively suppresses human T-lymphocyte activation in vitro. UK-78,282 binds to residues at the inner surface of the channel overlapping the site of action of verapamil.
    UK-78282 hydrochloride
  • HY-W037817
    Dimethyl L-glutamate
    		Inhibitor
    Dimethyl L-glutamate (Dimethyl glutamate), a membrane-permeable analog of Glutamate, can stimulate insulin release induced by Glucose. Dimethyl L-glutamate suppresses the KATP channel activities. Dimethyl L-glutamate inhibits E. gracilis growth and causes abnormal cell division. Dimethyl L-glutamate can be used in the research of diabetes, glucose transport, phosphorylation, and further metabolism.
    Dimethyl L-glutamate
  • HY-180919
    ERG-IN-5
    		Inhibitor
    ERG-IN-5 (Compound M1) is a metabolite of ERG-IN-4 (HY-180918), and it is a hERG potassium channel inhibitor with an IC50 of 1.5 μM. ERG-IN-5 is cytotoxic to MTAPdel HCT116 and its CC50 is 28 nM. ERG-IN-5 can be used for the study of colon cancer.
    ERG-IN-5
  • HY-14834AS
    Budiodarone-d10 tartrate
    		Inhibitor
    Budiodarone-d10 tartrate (ATI-2042-d10 tartrate) is the deuterium labeled Budiodarone tartrate (HY-14834A). Budiodarone (ATI-2042) tartrate is a chemical analogue of Amiodarone (HY-14187) with balanced, multiple cardiac ion channel (potassium, sodium and calcium channels) inhibiting activity. Budiodarone tartrate is an antiarrhythmic agent.
    Budiodarone-d<sub>10</sub> tartrate
Cat. No. Product Name / Synonyms Application Reactivity